Bio-Techne Collaborates on $300K Grant for Innovative CAR T-Cell Manufacturing Platform

Innovative CAR T-Cell Manufacturing Platform Receives $300,000 G-Rex Grant

In a significant advancement for gene and cell therapy, the Gates Institute's Translational Sciences Laboratory secures a $300,000 G-Rex Grant, in collaboration with ScaleReady, Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady. This grant is dedicated to developing a modular CAR T-cell manufacturing platform, aiming to streamline and improve the efficiency of cell and gene therapy (CGT) programs. Dr. Veena Krishnamoorthy, the Director of Translational Sciences at the Gates Institute, highlights the platform’s scalable and modular design. This innovative approach optimizes essential resources such as space, capital, and personnel while ensuring the health and quality of the cell products being manufactured.

The G-Rex Grant will allow the Gates Institute to implement a structured Design of Experiments (DoE) to refine CAR T-cell manufacturing processes. This approach focuses on evaluating critical variables to enhance product attributes, thus providing diverse manufacturing options for next-generation therapies. John Wilson, CEO of Wilson Wolf, commends the efforts of the Gates Institute in advancing innovative cell therapies aimed at treating serious cancers and rare diseases. The collaboration emphasizes the importance of partnerships in driving progress within the CGT field, as multiple stakeholders contribute expertise and technological resources to achieve common goals.

Additionally, the Gates Institute will benefit from early access to CellReady's G-CAR-T™ technology, recognized for its high-throughput capabilities in CAR T drug manufacturing. This collaboration not only signifies a commitment to advancing efficient CGT solutions but also exemplifies the synergistic potential of industry partnerships. ScaleReady's G-Rex Grant Program has previously allocated over $40 million in products to support CGT development, and the introduction of new initiatives further underscores its commitment to promoting scalable manufacturing practices in the industry.

In summary, the collaboration among ScaleReady, Bio-Techne, and other partners marks a pivotal moment in CAR T-cell manufacturing, potentially revolutionizing the landscape of cell and gene therapies. The strategic investments and innovative approaches highlighted in this grant announcement reflect a broader trend towards enhancing the efficiency and accessibility of critical therapeutic solutions for patients facing dire health challenges.